Supervised Treatment with Glanil® and Gluformin® Obviates need for Insulin Therapy in Patients with poorly controlled Type 2 Diabetes Mellitus
Objective: To determine the effect of supervised therapy with glibenclamide and metformin on glycaemic control in a selection of patients with poorly controlled type-2 diabetes mellitus in a Nigerian tertiary hospital. Materials and Methods: A prospective uncontrolled open label design was used. Subjects were randomly selected on the basis of poor glycaemic control (Fasting plasma glucose > 150 mg/dl, 2-hour post prandial glucose>180mg/dl, HbA1c >7%) and maximal doses of glibenclamide and metformin (15-20 mg, 2-3g respectively). Patients were seen at regular intervals with analysis of plasma glucose, glycated haemoglobin and supervised treatment (drugs were provided and there was open access to consulting offices and counseling). Results: There was significant reduction in the fasting plasma glucose, 2-hour post prandial plasma glucose and glycated haemoglobin at the end of the study. There were no adverse drug reactions recorded during the study and the drugs were well tolerated. Conclusion: SupervisedtreatmentwithMetformin(Gluformin®)andGlibenclamide(Glanil®)significantly improves glycaemic control in patients with type-2 diabetes mellitus.
Treatment , Diabetes mellitus , Insulin , Metformin , Research Subject Categories::MEDICINE
Coker AO, Fasanmade OA, Ohwovoriole AE. Supervised Treatment with Glanil® and Gluformin® Obviates need for Insulin Therapy in Patients with poorly controlled Type 2 Diabetes Mellitus. 2005;5(1):14-17